Antibe Therapeutics
Toronto
About Antibe Therapeutics
Antibe Therapeutics develops novel anti-inflammatory drugs that are improved versions of existing drugs. They focus on diseases characterized by inflammation, pain, and/or vascular dysfunction. Their drug design approach is to create new drugs by improving existing, proven drugs. The company's technology platform enables us to chemically link an existing drug to a hydrogen sulfide-releasing moeity. Hydrogen sulfide (H2S) is one of several so-called gaseous mediators. Gaseous mediators are naturally occurring substances found in the human body. Acting as neuromodulators, immunomodulators, and vasodilators, gaseous mediators such as H2S regulate fundamental cellular processes. Antibe believes that H2S has tremendous therapeutic potential. Antibe’s R&D is guided by a leading team of pharmaceutical researchers and advisors. The team includes a Nobel Prize winner, highly successful entrepreneurs, and senior scientists affiliated with major research institutions worldwide.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $71.9M
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2021)
- Ticker: cve:ATE
- Website: antibethera.com
- Phone: 416-922-3460
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/antibe-therapeutics-174467 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.